Health Care

Pfizer Inc. (NYSE:PFE) to Post Q1 2023 Earnings of $0.72 Per Share, Jefferies Financial Group Forecasts

/ / Health Care / ,

Jefferies Financial Group lowered their Q1 2023 earnings estimates for shares of Pfizer in a note issued to investors on Friday, March 17th. Jefferies Financial Group analyst A. Tewari now anticipates that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.78. Jefferies Financial Group has a “Hold” rating and a $43.00 price objective on the stock.

Pfizer Inc. (NYSE:PFE) to Post Q1 2023 Earnings of $0.72 Per Share, Jefferies Financial Group Forecasts Read Post »

Pfizer (NYSE:PFE) reported Q4 2022 Revenues of $24.3 Billion，update 2023 financial guidance

/ / Health Care /

January 31, 2023 — Pfizer Inc. (NYSE:PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Pfizer Inc. (NYSE:PFE) reported Q4 adjusted earnings  of $1.14 per diluted share, up from $0.79 a year earlier. Analysts polled by Capital IQ expected $1.04. Revenue for the quarter was $24.29 billion, up from $23.84 billion a year earlier. Analysts surveyed by Capital IQ expected $24.40 billion. The company said it is expecting fiscal 2023 adjusted earnings of $3.25 to $3.45 per diluted share. Analysts polled by Capital IQ are expecting $4.38. Revenue for the year is expected to range between $67 billion and $71 billion. Analysts surveyed by Capital IQ are expecting $74.23 billion. Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth，Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally。 Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth，Excluding Contributions

Pfizer (NYSE:PFE) reported Q4 2022 Revenues of $24.3 Billion，update 2023 financial guidance Read Post »

Pfizer (NYSE:PFE) to acquire Seagen (NASDAQ:SGEN) for $43 billion

/ / Health Care / ,

Pfizer Inc (NYSE:PFE) said Monday it agreed to buy biotech company Seagen Inc (NASDAQ:SGEN) for $43 billion to bolster its cancer treatment program. The New York-based drugmaker said it would pay $229 a share in cash, a nearly 33 percent premium to Seagen’s closing price of $172.61 on Friday. Seagen is headquartered in Bothel, Washington. Pfizer said it expects to fund most of the acquisition through $31 billion of new long-term debt, with the rest coming from short-term financing and cash on hand. Pfizer said it expects the deal with Seagen to have a neutral to slightly higher impact on adjusted earnings per share in the third to fourth full year after closing, and said it expects to achieve cost efficiencies of nearly $1 billion in the third full year.

Pfizer (NYSE:PFE) to acquire Seagen (NASDAQ:SGEN) for $43 billion Read Post »

Pfizer (NYSE:PFE) intends to acquire Seagen (NASDAQ:SGEN) for $229 per share in cash

/ / Health Care / ,

Pfizer (NYSE:PFE) will reportedly acquire Seagen (NASDAQ:SGEN) for $43 billion in total enterprise value for $229 per share in cash. Seagen’s risk-adjusted revenue contribution is expected to exceed $10 billion in 2030. Pfizer expects to finance the transaction primarily through a new borrowing of $31 billion of long-term debt, with the remainder coming from short-term financing and cash on hand.

Pfizer (NYSE:PFE) intends to acquire Seagen (NASDAQ:SGEN) for $229 per share in cash Read Post »

Scroll to Top